Idiopathic pulmonary fibrosis: Treatment update

被引：18

作者：

O'Connell, Oisin J. ^{[1
]}

Kennedy, Marcus P. ^{[1
]}

Henry, Michael T. ^{[1
]}

机构：

[1] Natl Univ Ireland Univ Coll Cork, Dept Resp Med, Cork, Ireland

来源：

ADVANCES IN THERAPY | 2011年 / 28卷 / 11期

关键词：

antifibrotic; idiopathic pulmonary fibrosis; patient management; treatment; PLACEBO-CONTROLLED TRIAL; ACID GASTROESOPHAGEAL-REFLUX; CELL LUNG-CANCER; INTERFERON GAMMA-1B; FACTOR EXPRESSION; PROGNOSTIC VALUE; HIGH PREVALENCE; DOUBLE-BLIND; PIRFENIDONE; HYPERTENSION;

D O I：

10.1007/s12325-011-0066-5

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.

引用

页码：986 / 999

页数：14

共 62 条

[1]

Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646

[2]

[Anonymous], 2002, Am J Respir Crit Care Med, V165, P277304, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]

[3] Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis [J].

Azuma, A ;

Nukiwa, T ;

Tsuboi, E ;

Suga, M ;

Abe, S ;

Nakata, K ;

Taguchi, Y ;

Nagai, S ;

Itoh, H ;

Ohi, M ;

Sato, A ;

Kudoh, S ;

Raghu, G .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) :1040-1047

[4] Pirfenidone for idiopathic pulmonary fibrosis [J].

Bouros, Demosthenes .

LANCET, 2011, 377 (9779) :1727-1729

[5] Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? [J].

Chambers, R. C. .

BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 :S367-S378

[6] Acute exacerbations of idiopathic pulmonary fibrosis [J].

Collard, Harold R. ;

Moore, Bethany B. ;

Flaherty, Kevin R. ;

Brown, Kevin K. ;

Kaner, Robert J. ;

King, Talmadge E., Jr. ;

Lasky, Joseph A. ;

Loyd, James E. ;

Noth, Imre ;

Olman, Mitchell A. ;

Raghu, Ganesh ;

Roman, Jesse ;

Ryu, Jay H. ;

Zisman, David A. ;

Hunninghake, Gary W. ;

Colby, Thomas V. ;

Egan, Jim J. ;

Hansell, David M. ;

Johkoh, Takeshi ;

Kaminski, Naftali ;

Kim, Dong Soon ;

Kondoh, Yasuhiro ;

Lynch, David A. ;

Mueller-Quernheim, Joachim ;

Myers, Jeffrey L. ;

Nicholson, Andrew G. ;

Selman, Moises ;

Toews, Galen B. ;

Wells, Athol U. ;

Martinez, Fernando J. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (07) :636-643

[7] Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis [J].

Collard, HR ;

Ryu, JH ;

Douglas, WW ;

Schwarz, MI ;

Curran-Everett, D ;

King, TE ;

Brown, KK .

CHEST, 2004, 125 (06) :2169-2174

[8]

Corte TJ, 2009, SARCOIDOSIS VASC DIF, V26, P7

[9] Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis [J].

Daniels, CE ;

Wilkes, MC ;

Edens, M ;

Kottom, TJ ;

Murphy, SJ ;

Limper, AH ;

Leof, EB .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (09) :1308-1316

[10] Imatinib Treatment for Idiopathic Pulmonary Fibrosis Randomized Placebo-controlled Trial Results [J].

Daniels, Craig E. ;

Lasky, Joseph A. ;

Limper, Andrew H. ;

Mieras, Kathleen ;

Gabor, Edith ;

Schroeder, Darrell R. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (06) :604-610

← 1 2 3 4 5 6 7 →